|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
DeSantis CE, Lin CC, Mariotto AB, Siegel
RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer
treatment and survivorship statistics, 2014. CA Cancer J Clin.
64:252–271. 2014.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Mitra AK, Agrahari V, Mandal A, Cholkar K,
Natarajan C, Shah S, Joseph M, Trinh HM, Vaishya R, Yang X, et al:
Novel delivery approaches for cancer therapeutics. J Control
Release. 219:248–268. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Talekar M, Tran TH and Amiji M:
Translational nano-medicines: Targeted therapeutic delivery for
cancer and inflammatory diseases. AAPS J. 17:813–827.
2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
You W and Henneberg M: Cancer incidence
increasing globally: The role of relaxed natural selection. Evol
Appl. 11:140–152. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Zhang Z, Zhou L, Xie N, Nice EC, Zhang T,
Cui Y and Huang C: Overcoming cancer therapeutic bottleneck by drug
repurposing. Signal Transduct Target Ther. 5(113)2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
World Health Organization (WHO): Cancer:
Key facts. WHO, Geneva, 2018. https://www.who.int/news-room/fact-sheets/detail/cancer.
Accessed September 12, 2018.
|
|
10
|
Lewis LD: Cancer pharmacotherapy: 21st
century ‘magic bullets’ and changing paradigms. Br J Clin
Pharmacol. 62:1–4. 2006.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Samadi AK, Bilsland A, Georgakilas AG,
Amedei A, Amin A, Bishayee A, Azmi AS, Lokeshwar BL, Grue B, Panis
C, et al: A multi-targeted approach to suppress tumor-promoting
inflammation. Semin Cancer Biol. 35 (Suppl):S151–S184.
2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Shaked Y: The pro-tumorigenic host
response to cancer therapies. Nat Rev Cancer. 19:667–685.
2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Guo Q, Jin Z, Yuan Y, Liu R, Xu T, Wei H,
Xu X, He S, Chen S, Shi Z, et al: Corrigendum to ‘New mechanisms of
tumor-associated macrophages on promoting tumor progression: Recent
research advances and potential targets for tumor immunotherapy’. J
Immunol Res. 2018(6728474)2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Larionova I, Cherdyntseva N, Liu T,
Patysheva M, Rakina M and Kzhyshkowska J: Interaction of
tumor-associated macrophages and cancer chemotherapy.
Oncoimmunology. 8(1596004)2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Mantovani A and Allavena P: The
interaction of anticancer therapies with tumor-associated
macrophages. J Exp Med. 212:435–445. 2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Mantovani A, Marchesi F, Malesci A, Laghi
L and Allavena P: Tumour-associated macrophages as treatment
targets in oncology. Nat Rev Clin Oncol. 14:399–416.
2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Nielsen SR and Schmid MC: Macrophages as
key drivers of cancer progression and metastasis. Mediators
Inflamm. 2017(9624760)2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Prill S, Rebstock J, Tennemann A, Körfer
J, Sönnichsen R, Thieme R, Gockel I, Lyros O, Monecke A, Wittekind
C, et al: Tumor-associated macrophages and individual
chemo-susceptibility are influenced by iron chelation in human
slice cultures of gastric cancer. Oncotarget. 10:4731–4742.
2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Lampiasi N, Russo R and Zito F: The
alternative faces of macrophage generate osteoclasts. Biomed Res
Int. 2016(9089610)2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Lin Y, Xu J and Lan H: Tumor-associated
macrophages in tumor metastasis: Biological roles and clinical
therapeutic applications. J Hematol Oncol. 12(76)2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Mantovani A, Sica A, Sozzani S, Allavena
P, Vecchi A and Locati M: The chemokine system in diverse forms of
macrophage activation and polarization. Trends Immunol. 25:677–686.
2004.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Porta C, Riboldi E, Ippolito A and Sica A:
Molecular and epigenetic basis of macrophage polarized activation.
Semin Immunol. 27:237–248. 2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Schliefsteiner C, Peinhaupt M, Kopp S,
Lögl J, Lang-Olip I, Hiden U, Heinemann A, Desoye G and Wadsack C:
Human placental hofbauer cells maintain an anti-inflammatory M2
phenotype despite the presence of gestational diabetes mellitus.
Front. Immunol. 8(888)2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Yao Y, Xu XH and Jin L: Macrophage
polarization in physiological and pathological pregnancy. Front
Immunol. 10(792)2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Mantovani A, Bottazzi B, Colotta F,
Sozzani S and Ruco L: The origin and function of tumor-associated
macrophages. Immunol Today. 13:265–270. 1992.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Mantovani A and Locati M: Tumor-associated
macrophages as a paradigm of macrophage plasticity, diversity, and
polarization: Lessons and open questions. Arterioscler Thromb Vasc
Biol. 33:1478–1483. 2013.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Stein M, Keshav S, Harris N and Gordon S:
Interleukin 4 potently enhances murine macrophage mannose receptor
activity: A marker of alternative immunologic macrophage
activation. J Exp Med. 176:287–292. 1992.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Murray PJ, Allen JE, Biswas SK, Fisher EA,
Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence
T, et al: Macrophage activation and polarization: Nomenclature and
experimental guidelines. Immunity. 41:14–20. 2014.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Qian BZ and Pollard JW: Macrophage
diversity enhances tumor progression and metastasis. Cell.
141:39–51. 2010.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Sawa-Wejksza K and Kandefer-Szerszeń M:
Tumor-associated macrophages as target for antitumor therapy. Arch
Immunol Ther Exp (Warsz). 66:97–111. 2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zhou J, Tang Z, Gao S, Li C, Feng Y and
Zhou X: Tumor-Associated Macrophages: Recent insights and
therapies. Front Oncol. 10(188)2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Gratchev A, Guillot P, Hakiy N, Politz O,
Orfanos CE, Schledzewski K and Goerdt S: Alternatively activated
macrophages differentially express fibronectin and its splice
variants and the extracellular matrix protein betaIG-H3. Scand J
Immunol. 53:386–392. 2001.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Gratchev A, Kzhyshkowska J, Kannookadan S,
Ochsenreiter M, Popova A, Yu X, Mamidi S, Stonehouse-Usselmann E,
Muller-Molinet I, Gooi L and Goerdt S: Activation of a
TGF-beta-specific multistep gene expression program in mature
macrophages requires glucocorticoid-mediated surface expression of
TGFbeta receptor II. J Immunol. 180:6553–6565. 2008.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Goerdt S, Politz O, Schledzewski K, Birk
R, Gratchev A, Guillot P, Hakiy N, Klemke CD, Dippel E, Kodelja V
and Orfanos CE: Alternative versus classical activation of
macrophages. Pathobiology. 67:222–226. 1999.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Glass CK and Natoli G: Molecular control
of activation and priming in macrophages. Nat Immunol. 17:26–33.
2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Van Ginderachter JA, Movahedi K,
Hassanzadeh Ghassabeh G, Meerschaut S, Beschin A, Raes G and De
Baetselier P: Classical and alternative activation of mononuclear
phagocytes: Picking the best of both worlds for tumor promotion.
Immunobiology. 211:487–501. 2006.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Osborn O and Olefsky JM: The cellular and
signaling networks linking the immune system and metabolism in
disease. Nat Med. 18:363–374. 2012.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Rőszer T: Understanding the Mysterious M2
macrophage through activation markers and effector mechanisms.
Mediators Inflamm. 2015(816460)2015.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Tamura R, Tanaka T, Yamamoto Y, Akasaki Y
and Sasaki H: Dual role of macrophage in tumor immunity.
Immunotherapy. 10:899–909. 2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Jinushi M and Komohara Y: Tumor-associated
macrophages as an emerging target against tumors: Creating a new
path from bench to bedside. Biochim Biophys Acta. 1855:123–1230.
2015.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Wynn TA, Chawla A and Pollard JW:
Macrophage biology in development, homeostasis and disease. Nature.
496:445–455. 2013.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Ginhoux F and Jung S: Monocytes and
macrophages: Developmental pathways and tissue homeostasis. Nat Rev
Immunol. 14:392–404. 2014.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Lewis CE, Harney AS and Pollard JW: The
multifaceted role of perivascular macrophages in tumors. Cancer
Cell. 30:18–25. 2016.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Ngambenjawong CH, Heather H and Suzie H:
Progress in tumor-associated macrophage (TAM)-targeted
therapeutics. Adv Drug Deliv Rev. 114:206–221. 2017.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Evans R and Alexander P: Cooperation of
immune lymphoid cells with macrophages in tumour immunity. Nature.
228:620–622. 1970.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Chen Y, Song Y, Du W, Gong L, Chang H and
Zou Z: Tumor-associated macrophages: An accomplice in solid tumor
progression. J Biomed Sci. 26(78)2019.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Jeannin P, Paolini L, Adam C and Delneste
Y: The roles of CSFs on the functional polarization of
tumor-associated macrophages. FEBS J. 285:680–699. 2018.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Wang HW and Joyce JA: Alternative
activation of tumor-associated macrophages by IL-4: Priming for
protumoral functions. Cell Cycle. 9:4824–4835. 2010.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Quail DF and Joyce JA: Microenvironmental
regulation of tumor progression and metastasis. Nat Med.
19:1423–1437. 2013.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Caux C, Ramos RN, Prendergast GC,
Bendriss-Vermare N and Ménétrier-Caux C: A milestone review on how
macrophages affect tumor growth. Cancer Res. 76:6439–6442.
2016.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Allavena P, Sica A, Solinas G, Porta C and
Mantovani A: The inflammatory micro-environment in tumor
progression: The role of tumor-associated macrophages. Crit Rev
Oncol Hematol. 66:1–9. 2008.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Ostuni R, Kratochvill F, Murray PJ and
Natoli G: Macrophages and cancer: From mechanisms to therapeutic
implications. Trends Immunol. 36:229–239. 2017.
|
|
53
|
Kreider T, Anthony RM, Urban JF Jr and
Gause WC: Alternatively activated macrophages in helminth
infections. Curr Opin Immunol. 19:448–453. 2007.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Wang Q, Ni H, Lan L, Wei X, Xiang R and
Wang Y: Fra-1 pro-tooncogene regulates IL-6 expression in
macrophages and promotes the generation of M2d macrophages. Cell
Res. 20:701–712. 2010.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Quail DF and Joyce JA: Molecular pathways:
Deciphering mechanisms of resistance to macrophage-targeted
therapies. Clin Cancer Res. 23:876–884. 2017.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Yuan ZY, Luo RZ, Peng RJ, Wang SS and Xue
C: High infiltration of tumor-associated macrophages in
triple-negative breast cancer is associated with a higher risk of
distant metastasis. Onco Targets Ther. 7:1475–1480. 2014.PubMed/NCBI View Article : Google Scholar
|
|
57
|
He Y, Zhang M, Wu X, Sun X, Xu T, He Q and
Di W: High MUC2 expression in ovarian cancer is inversely
associated with the M1/M2 ratio of tumor-associated macrophages and
patient survival time. PLoS One. 8(e79769)2013.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Ding P, Wang W, Wang J, Yang Z and Xue L:
Expression of tumor-associated macrophage in progression of human
glioma. Cell Biochem Biophys. 70:1625–1631. 2014.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Pantano F, Berti P, Guida FM, Perrone G,
Vincenzi B, Amato MM, Righi D, Dell'Aquila E, Graziano F, Catalano
V, et al: The role of macrophages polarization in predicting
prognosis of radically resected gastric cancer patients. J Cell Mol
Med. 17:1415–1421. 2013.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Ruffell B, Affara NI and Coussens LM:
Differential macrophage programming in the tumor microenvironment.
Trends Immunol. 33:119–126. 2012.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Mei J, Xiao Z, Guo C, Pu Q, Ma L, Liu C,
Lin F, Liao H, You Z and Liu L: Prognostic impact of
tumor-associated macrophage infiltration in non-small cell lung
cancer: A systemic review and meta-analysis. Oncotarget.
7:34217–34228. 2016.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Chanmee T, Ontong P, Konno K and Itano N:
Tumor-associated macrophages as major players in the tumor
icroenvironment. Cancers (Basel). 6:1670–1690. 2014.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Junankar S, Shay G, Jurczyluk J, Ali N,
Down J, Pocock N, Parker A, Nguyen A, Sun S, Kashemirov B, et al:
Real-time intravital imaging establishes tumor-associated
macrophages as the extraskeletal target of bisphosphonate action in
cancer. Cancer Discov. 5:35–42. 2015.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Coscia M, Quaglino E, Iezzi M, Curcio C,
Pantaleoni F, Riganti C, Holen I, Monkkonen H, Boccadoro M, Forni
G, et al: Zoledronic acid repolarizes tumour-associated macrophages
and inhibits mammary carcinogenesis by targeting the mevalonate
pathway. J Cell Mol Med. 14:2803–2815. 2010.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Rogers TL and Holen I: Tumour macrophages
as potential targets of bisphosphonates. J Transl Med.
9(177)2011.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Rogers TL, Wind N, Hughes R, Nutter F,
Brown HK, Vasiliadou I, Ottewell PD and Holen I: Macrophages as
potential targets for zoledronic acid outside the skeleton-evidence
from in vitro and in vivo models. Cell Oncol (Dordr). 36:505–514.
2013.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Ali N, Jurczyluk J, Shay G, Tnimov Z,
Alexandrov K, Munoz MA, Skinner OP, Pavlos NJ and Rogers MJ: A
highly sensitive prenylation assay reveals in vivo effects of
bisphosphonate drug on the Rab prenylome of macrophages outside the
skeleton. Small GTPases. 6:202–211. 2015.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Tardoski S, Ngo J, Gineyts E, Roux JP,
Clézardin PH and Melodelima D: Low-intensity continuous ultrasound
triggers effective bisphosphonate anticancer activity in breast
cancer. Sci Rep. 5(16354)2015.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Sousa S, Auriola S, Mönkkönen J and Mааttа
J: Liposome encapsulated zoledronate favours M1-like behaviour in
murine macrophages cultured with soluble factors from breast cancer
cells. BMC Cancer. 15(4)2015.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Hiroshima Y, Maawy A, Hassanein MK, Menen
R, Momiyama M, Murakami T, Miwa S, Yamamoto M, Uehara F, Yano S, et
al: The tumor-educated-macrophage increase of malignancy of human
pancreatic cancer is prevented by zoledronic acid. PLoS One.
9(e103382)2014.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Esser AK, Schmieder AH, Ross MH, Xiang J,
Su X, Cui G, Zhang H, Yang X, Allen JS, Williams T, et al:
Dual-therapy with αvβ3-targeted Sn2 lipase-labile
fumagillin-prodrug nanoparticles and zoledronic acid in the Vx2
rabbit tumor model. Nanomedicine. 12:201–211. 2016.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Zekri J, Mansour M and Karim SM: The
anti-tumour effects of zoledronic acid. J Bone Oncol. 3:25–35.
2014.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Kopecka J, Porto S, Lusa S, Gazzano E,
Salzano G, Pinzòn-Daza ML, Giordano A, Desiderio V, Ghigo D, De
Rosa G, et al: Zoledronic acid-encapsulating self-assembling
nanoparticles and doxorubicin: A combinatorial approach to overcome
simultaneously chemoresistance and immunoresistance in breast
tumors. Oncotarget. 7:20753–20772. 2016.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Fowler DW, Copier J, Dalgleish AG and
Bodman-Smith MD: Zoledronic acid renders human M1 and M2
macrophages susceptible to Vδ2+ γδ T cell cytotoxicity
in a perforin-dependent manner. Cancer Immunol Immunother.
66:1205–1215. 2017.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Lavin Y and Merad M: Macrophages:
Gatekeepers of tissue integrity. Cancer Immunol Res. 1:201–209.
2013.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Gul N and van Egmond M: Antibody-dependent
phagocytosis of tumor cells by macrophages: A potent effector
mechanism of monoclonal antibody. Therapy of cancer. Cancer Res.
75:5008–5013. 2015.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Tipton TR, Roghanian A, Oldham RJ, Carter
MJ, Cox KL, Mockridge CI, French RR, Dahal LN, Duriez PJ,
Hargreaves PG, et al: Antigenic modulation limits the effector cell
mechanisms employed by type I anti-CD20 monoclonal antibodies.
Blood. 125:1901–1909. 2015.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Shi Y, Fan X, Deng H, Brezski RJ, Rycyzyn
M, Jordan RE, Strohl WR, Zou Q, Zhang N and An Z: Trastuzumab
triggers phagocytic killing of high HER2 cancer cells in vitro and
in vivo by interaction with Fcgamma receptors on macrophages. J
Immunol. 194:4379–4386. 2015.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Grugan KD, McCabe FL, Kinder M, Greenplate
AR, Harman BC, Ekert JE, van Rooijen N, Anderson GM, Nemeth JA,
Strohl WR, et al: Tumor-associated macrophages promote invasion
while retaining Fc-dependent anti-tumor function. J Immunol.
189:5457–5466. 2012.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Taylor RP and Lindorfer MA: Analyses of
CD20 monoclonal antibody-mediated tumor cell killing mechanisms:
Rational design of dosing strategies. Mol Pharmacol. 86:485–491.
2014.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Richards JO, Karki S, Lazar GA, Chen H,
Dang W and Desjarlais JR: Optimization of antibody binding to
FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol
Cancer Ther. 7:2517–2527. 2008.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Brandsma AM, Ten Broeke T, Nederend M,
Meulenbroek LA, van Tetering G, Meyer S, Jansen JH, Beltrán
Buitrago MA, Nagelkerke SQ, Németh I, et al: Simultaneous Targeting
of FcgammaRs and FcalphaRI enhances tumor cell killing. Cancer
Immunol Res. 3:1316–1324. 2015.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Josephs DH, Bax HJ, Dodev T, Georgouli M,
Nakamura M, Pellizzari G, Saul L, Karagiannis P, Cheung A, Herraiz
C, et al: Anti-folate receptor-α IgE but not IgG recruits
macrophages to attack tumors via TNF-α/MCP-1 signaling. Cancer Res.
77:1127–1141. 2017.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Cespedes MV, Guillen MJ, Lopez-Casas PP,
Sarno F, Gallardo A, Álamo P, Cuevas C, Hidalgo M, Galmarini CM,
Allavena P, et al: Lurbinectedin induces depletion of
tumor-associated macrophages, an essential component of its in vivo
synergism with gemcitabine, in pancreatic adenocarcinoma mouse
models. Dis Model Mech. 9:1461–1471. 2016.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Germano G, Frapolli R, Belgiovine C,
Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M,
Pasqualini F, et al: Role of macrophage targeting in the antitumor
activity of trabectedin. Cancer Cell. 23:249–262. 2013.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Liguori M, Buracchi C, Pasqualini F,
Bergomas F, Pesce S, Sironi M, Grizzi F, Mantovani A, Belgiovine C
and Allavena P: Functional TRAIL receptors in monocytes and
tumor-associated macrophages: A possible targeting pathway in the
tumor microenvironment. Oncotarget. 7:41662–41676. 2016.PubMed/NCBI View Article : Google Scholar
|
|
87
|
De Palma M and Lewis CE: Macrophage
regulation of tumor responses to anticancer therapies. Cancer Cell.
23:277–286. 2013.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Kodumudi KN, Woan K, Gilvary DL, Sahakian
E, Wei S and Djeu JY: A novel chemoimmunomodulating property of
docetaxel: Suppression of myeloid-derived suppressor cells in tumor
bearers. Clin Cancer Res. 16:4583–4594. 2010.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Guerriero JL, Ditsworth D, Catanzaro JM,
Sabino G, Furie MB, Kew RR, Crawford HC and Zong WX: DNA alkylating
therapy induces tumor regression through an HMGB1-mediated
activation of innate immunity. J Immunol. 186:3517–3526.
2011.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Bryniarski K, Szczepanik M, Ptak M,
Zemelka M and Ptak W: Influence of cyclophosphamide and its
metabolic products on the activity of peritoneal macrophages in
mice. Pharmacol Rep. 61:550–557. 2009.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Baghdadi M, Wada H, Nakanishi S, Abe H,
Han N, Putra WE, Endo D, Watari H, Sakuragi N, Hida Y, et al:
Chemotherapy-Induced IL34 enhances immunosuppression by
tumor-associated macrophages and mediates survival of
chemoresistant lung cancer cells. Cancer Res. 76:6030–6042.
2016.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Zhou Y and Dai Z: New Strategies in the
design of nanomedicines to oppose uptake by the mononuclear
phagocyte system and enhance cancer therapeutic efficacy. Chem
Asian J. 13:3333–3340. 2018.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Niu M, Naguib YW, Aldayel AM, Shi YC,
Hursting SD, Hersh MA and Cui Z: Biodistribution and in vivo
activities of tumor-associated macrophage-targeting nanoparticles
incorporated with doxorubicin. Mol Pharm. 11:4425–4436.
2014.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Ngambenjawong C, Cieslewicz M, Schellinger
JG and Pun SH: Synthesis and evaluation of multivalent M2pep
peptides for targeting alternatively activated M2macrophages. J
Control Release. 224:103–111. 2016.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Silva VL and Al-Jamal WT: Exploiting the
cancer niche: Tumor-associated macrophages and hypoxia as promising
synergistic targets for Nano-based therapy. J Control Release.
253:82–96. 2017.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Andón FT, Digifico E, Maeda A, Erreni M,
Mantovani A, Alonso MJ and Allavena P: Targeting tumor associated
macrophages: The new challenge for nanomedicine. Semin Immunol.
34:103–113. 2017.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Li M, Zhang F, Su Y, Zhou J and Wang W:
Nanoparticles designed to regulate tumor microenvironment for
cancer therapy. Life Sci. 201:37–44. 2018.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Tabata Y and Ikada Y: Effect of the size
and surface charge of polymer microspheres on their phagocytosis by
macrophage. Biomaterials. 9:356–362. 1988.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Champion JA and Mitragotri S: Role of
target geometry in phagocytosis. Proc Natl Acad Sci USA.
103:4930–4934. 2006.PubMed/NCBI View Article : Google Scholar
|
|
100
|
He C, Hu Y, Yin L, Tang C and Yin C:
Effects of particle size and surface charge on cellular uptake and
biodistribution of polymeric nanoparticles. Biomaterials.
31:3657–3666. 2010.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Chang YN, Guo H, Li J, Song Y, Zhang M,
Jin J, Xing G and Zhao Y: Adjusting the balance between effective
loading and vector migration of macrophage vehicles to deliver
nanoparticles. PLoS One. 8(e76024)2013.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Yu SS, Lau CM, Thomas SN, Jerome WG, Maron
DJ, Dickerson JH, Hubbell JA and Giorgio TD: Size- and
charge-dependent nonspecific uptake of PEGylated nanoparticles by
macrophages. Int J Nanomedicine. 7:799–813. 2012.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Herd H, Daum N, Jones AT, Huwer H,
Ghandehari H and Lehr CM: Nanoparticle geometry and surface
orientation influence mode of cellular uptake. ACS Nano.
7:1961–1973. 2013.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Li Z, Sun L, Zhang Y, Dove AP, O'Reilly RK
and Chen G: Shape effect of Glyco-nanoparticles on macrophage
cellular uptake and immune response. ACS Macro Lett. 5:1059–1064.
2016.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Cieslewicz M, Tang J, Yu JL, Cao H,
Zavaljevski M, Motoyama K, Lieber A, Raines EW and Pun SH: Targeted
delivery of proapoptotic peptides to tumor-associated macrophages
improves survival. Proc Natl Acad Sci USA. 110:15919–15924.
2013.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Ngambenjawong C and Pun SH: Multivalent
polymers displaying M2 macrophage-targeting peptides improve target
binding avidity and serum stability. ACS Biomater Sci Eng.
3:2050–2053. 2017.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Huang WC, Chen SH, Chiang WH, Huang CW, Lo
CL, Chern CS and Chiu HC: Tumor microenvironment-responsive
nanoparticle delivery of chemotherapy for enhanced selective
cellular uptake and transportation within tumor. Biomacromolecules.
17:3883–3892. 2016.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Poupot R, Goursat C and Fruchon S:
Multivalent nanosystems: Targeting monocytes/macrophages. Int J
Nanomedicine. 13:5511–5521. 2018.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Cupaioli FA, Zucca FA, Boraschi D and
Zecca L: Engineered nanoparticles How brain friendly is this new
guest? Prog Neurobiol. 119-120:20–38. 2014.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Costa A, Sarmento B and Seabra V:
Mannose-functionalized solid lipid nanoparticles are effective in
targeting alveolar macrophages. Eur J Pharm Sci. 114:103–113.
2018.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Sarwar HS, Ashraf S, Akhtar S, Sohail MF,
Hussain SZ, Rafay M, Yasinzai M, Hussain I and Shahnaz G:
Mannosylated thiolated polyethylenimine nanoparticles for the
enhanced efficacy of antimonial drug against Leishmaniasis.
Nanomedicine (Lond). 13:25–41. 2018.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Fallarini S, Paoletti T, Battaglini CO,
Ronchi P, Lay L, Bonomi R, Jha S, Mancin F, Scrimin P and Lombardi
G: Factors affecting T cell responses induced by fully synthetic
glyco-gold-nanoparticles. Nanoscale. 5:390–400. 2013.PubMed/NCBI View Article : Google Scholar
|
|
113
|
He H, Yuan Q, Bie J, Wallace RL, Yannie
PJ, Wang J, Lancina MG III, Zolotarskaya OY, Korzun W, Yang H and
Ghosh S: Development of mannose functionalized dendrimeric
nanoparticles for targeted delivery to macrophages: Use of this
platform to modulate atherosclerosis. Transl Res. 193:13–30.
2018.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Sun X, Li W, Zhang X, Qi M, Zhang Z, Zhang
XE and Cui Z: In vivo targeting and imaging of atherosclerosis
using multifunctional virus-like particles of Simian Virus. Nano
Lett. 16:6164–6171. 2016.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Zhu S, Niu M, O'Mary H and Cui Z:
Targeting of tumor-associated macrophages made possible by
PEG-sheddable, mannose-modified nanoparticles. Mol Pharm.
10:3525–3530. 2013.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Qian Y, Qiao S, Dai Y, Xu G, Dai B, Lu L,
Yu X, Luo Q and Zhang Z: Molecular-targeted immunotherapeutic
strategy for melanoma via dual-targeting nanoparticles delivering
small interfering RNA to tumor-associated macrophages. ACS Nano.
11:9536–9549. 2017.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Lamanna G, Russier J, Dumortier H and
Bianco A: Enhancement of anti-inflammatory drug activity by
multivalent adamantane-based dendrons. Biomaterials. 33:5610–5617.
2012.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Lee S, Kivimae S, Dolor A and Szoka FC:
Macrophage-based cell therapies: The long and winding road. J
Control Release. 240:527–540. 2016.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Choi J, Kim HY, Ju EJ, Jung J, Park J,
Chung HK, Lee JS, Lee JS, Park HJ, Song SY, et al: Use of
macrophages to deliver therapeutic and imaging contrast agents to
tumors. Biomaterials. 33:4195–4203. 2012.PubMed/NCBI View Article : Google Scholar
|
|
120
|
Madsen SJ, Baek SK, Makkouk AR, Krasieva T
and Hirschberg H: Macrophages as cell-based delivery systems for
nanoshells in photothermal therapy. Ann Biomed Eng. 40:507–515.
2012.PubMed/NCBI View Article : Google Scholar
|
|
121
|
Ikehara Y, Niwa T, Biao L, Ikehara SK,
Ohashi N, Kobayashi T, Shimizu Y, Kojima N and Nakanishi H: A
carbohydrate recognition-based drug delivery and controlled release
system using intraperitoneal macrophages as a cellular vehicle.
Cancer Res. 66:8740–8748. 2006.PubMed/NCBI View Article : Google Scholar
|
|
122
|
Miller MA, Zheng YR, Gadde S, Pfirschke C,
Zope H, Engblom C, Kohler RH, Iwamoto Y, Yang KS, Askevold B, et
al: Tumour-associated macrophages act as a slow-release reservoir
of nano-therapeutic Pt(IV) pro-drug. Nat Commun.
6(8692)2015.PubMed/NCBI View Article : Google Scholar
|
|
123
|
Tanei T, Leonard F, Liu X, Alexander JF,
Saito Y, Ferrari M, Godin B and Yokoi K: Redirecting transport of
nanoparticle albumin-bound paclitaxel to macrophages enhances
therapeutic efficacy against liver metastases. Cancer Res.
76:429–439. 2016.PubMed/NCBI View Article : Google Scholar
|
|
124
|
Dou H, Destache CJ, Morehead JR, Mosley
RL, Boska MD, Kingsley J, Gorantla S, Poluektova L, Nelson JA,
Chaubal M, et al: Development of a macrophage-based nanoparticle
platform for antiretroviral drug delivery. Blood. 108:2827–2835.
2006.PubMed/NCBI View Article : Google Scholar
|
|
125
|
Dou H, Grotepas CB, McMillan JM, Destache
CJ, Chaubal M, Werling J, Kipp J, Rabinow B and Gendelman HE:
Macrophage delivery of nanoformulated antiretroviral drug to the
brain in a murine model of neuroAIDS. J Immunol. 183:661–669.
2009.PubMed/NCBI View Article : Google Scholar
|
|
126
|
Zhao Y, Haney MJ, Klyachko NL, Li S, Booth
SL, Higginbotham SM, Jones J, Zimmerman MC, Mosley RL, Kabanov AV,
et al: Polyelectrolyte complex optimization for macrophage delivery
of redox enzyme nanoparticles. Nanomedicine (Lond). 6:25–42.
2011.PubMed/NCBI View Article : Google Scholar
|
|
127
|
Klyachko NL, Haney MJ, Zhao Y, Manickam
DS, Mahajan V, Suresh P, Hingtgen SD, Mosley RL, Gendelman HE,
Kabanov AV and Batrakova EV: Macrophages offer a paradigm switch
for CNS delivery of therapeutic proteins. Nanomedicine (Lond).
9:1403–1422. 2014.PubMed/NCBI View Article : Google Scholar
|
|
128
|
Muthana M, Kennerley AJ, Hughes R, Fagnano
E, Richardson J, Paul M, Murdoch C, Wright F, Payne C, Lythgoe MF,
et al: Directing cell therapy to anatomic target sites in vivo with
magnetic resonance targeting. Nat Commun. 6(8009)2015.PubMed/NCBI View Article : Google Scholar
|
|
129
|
Han J, Zhen J, Du Nguyen V, Go G, Choi Y,
Ko SY, Park JO and Park S: Hybrid-actuating macrophage-based
microrobots for active cancer therapy. Sci Rep.
6(28717)2016.PubMed/NCBI View Article : Google Scholar
|
